查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1393540

全球子宮癌藥物市場－產業趨勢與預測（截至2030年）

Global Uterine Cancer Drug Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 379 Pages | 商品交期: 請詢問到貨日

價格

全球子宮癌藥物市場將從2022年的23,162,144.1億美元增至2030年的4,269,049.34百萬美元，2023-2030年預測期間複合年增長率為8.5%。

本報告針對全球子宮癌治療藥物市場進行研究分析，提供產業趨勢與預測、促進與抑制因素、公司動態等資訊。

目錄

第 1 章簡介

第 2 章市場區隔

第 3 章執行摘要

第 4 章重要考量

  • PESTEL模型
  • 波特五力分析
  • 流行病學

第 5 章全球子宮癌藥物市場、監管架構

  • 摘要
  • 美國法規
  • 加拿大法規
  • 歐洲法規
  • 中國法規
  • 日本法規
  • 澳洲法規
  • 印度法規
  • 巴西法規
  • 南非法規

第 6 章市場概論

  • 促進因素
    • 全球子宮癌發生率不斷上升
    • 子宮癌標靶治療的進展
    • 提高對子宮癌的認識
    • 主要企業聯盟和合作關係的增加
  • 抑制因素
    • 子宮癌治療費用高昂
    • 與抗癌藥物相關的副作用和毒性
  • 機會
    • 基因組分析和生物標記發現的進展
    • 擴大子宮癌治療的研發活動
  • 作業
    • 子宮癌藥物市場的監管障礙
    • 子宮癌治療中的抗藥性

第 7 章全球子宮癌治療市場：依癌症類型劃分

  • 摘要
  • 子宮內膜癌
    • 子宮癌肉瘤
    • 漿液性腺癌
    • 腺鱗癌
    • 其他
  • 子宮肉瘤
    • 子宮平滑肌肉瘤
    • 子宮內膜間質肉瘤
    • 未分化肉瘤

第 8 章全球子宮癌治療市場：依治療方法分類

  • 摘要
  • 化療
    • PACLITAXEL 102
    • CARBOPLATIN 102
    • CISPLATIN 102
    • DOXORUBICIN 102
    • DOCETAXEL 102
    • 其他
  • 免疫治療
  • 荷爾蒙療法
    • 黃體素
    • 芳香□抑制劑
    • 黃體生成素釋放激素激動劑
    • 其他
  • 標靶治療
    • LENVATINAB
    • BEVACIZUMAB
    • MTOR INHIBITORS
  • 其他

第 9 章全球子宮癌藥物市場：依藥物類型

  • 摘要
  • 通用
  • 品牌
    • KEYTRUDA 114
    • LENVIMA 114
    • PROVERA 115
    • TEMODAR 115
    • JEMPERLI 115
    • 其他

第 10 章全球子宮癌治療藥物市場：依年齡層劃分

  • 摘要
  • 老人
  • 成人

第 11 章全球子宮癌藥物市場：依給藥途徑劃分

  • 摘要
  • 注射用
  • 口服

第 12 章全球子宮癌藥物市場：以最終用戶劃分

  • 摘要
  • 醫院
    • 私人
    • 公開
  • 癌症中心
  • 專科診所
  • 其他

第 13 章全球子宮癌治療藥物市場：依通路劃分

  • 摘要
  • 直接提供
  • 零售銷售
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 其他

第 14 章全球子宮癌治療市場：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 俄羅斯
    • 義大利
    • 西班牙
    • 土耳其
    • 比利時
    • 荷蘭
    • 瑞士
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 韓國
    • 紐西蘭
    • 新加坡
    • 泰國
    • 馬來西亞
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 埃及
    • 科威特
    • 其他中東地區

第 15 章全球子宮癌治療藥物市場及企業狀況

  • 公司股票分析：全球
  • 公司股票分析：北美
  • 公司股票分析：歐洲
  • 公司股票分析：亞太地區

第 16 章SWOT分析

第 17 章公司簡介

  • MERCK & CO., INC.
  • EISAI CO., LTD.
  • SANOFI
  • PFIZER INC.
  • TEVA PHARMACEUTICALS USA, INC.
  • ACCORD HEALTHCARE US.
  • AMNEAL PHARMACEUTICALS LLC
  • BAXTER
  • ELI LILLY AND COMPANY
  • GETWELL ONCOLOGY
  • GSK PLC.
  • HIKMA PHARMACEUTICALS PLC
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • VIATRIS INC.
  • VIRTUS

第 18 章調查

第 19 章相關報告

The global uterine cancer drugs market is expected to reach USD 4,269,049.34 million by 2030 from USD 2,316,214.41 million in 2022, growing at a CAGR of 8.5% during the forecast period of 2023 to 2030.

Market Segmentation

Global Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Uterine Cancer Drugs Market Dynamics

  • Driver
  • Rising incidence of uterine cancer worldwide
  • Restraint
  • High cost of uterine cancer treatment
  • Opportunity
  • Advancement in genomic profiling and biomarker discovery

Market Players

Some of the major market players operating in the global uterine cancer drugs market are listed below:

  • Baxter
  • Accord BioPharma, Inc.
  • Eli Lilly and Company
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius SE & Co. KGaA
  • Viatris Inc.
  • Sanofi
  • Teva Pharmaceuticals USA, Inc.
  • Amneal Pharmaceuticals LLC
  • Merck & Co., Inc.
  • GSK plc.
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Virtus
  • Getwell Oncology

TABLE OF CONTENTS

1 INTRODUCTION 47

  • 1.1 OBJECTIVES OF THE STUDY 47
  • 1.2 MARKET DEFINITION 47
  • 1.3 OVERVIEW OF THE GLOBAL UTERINE CANCER DRUGS MARKET 47
  • 1.4 LIMITATIONS 49
  • 1.5 MARKETS COVERED 49

2 MARKET SEGMENTATION 52

  • 2.1 MARKETS COVERED 52
  • 2.2 GEOGRAPHICAL SCOPE 53
  • 2.3 YEARS CONSIDERED FOR THE STUDY 54
  • 2.4 CURRENCY AND PRICING 54
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
  • 2.6 MULTIVARIATE MODELLING 58
  • 2.7 CANCER TYPE LIFELINE CURVE 58
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
  • 2.9 DBMR MARKET POSITION GRID 60
  • 2.10 MARKET END USER COVERAGE GRID 61
  • 2.11 VENDOR SHARE ANALYSIS 62
  • 2.12 SECONDARY SOURCES 63
  • 2.13 ASSUMPTIONS 63

3 EXECUTIVE SUMMARY 64

4 PREMIUM INSIGHTS 67

  • 4.1 PESTEL'S MODEL 70
  • 4.2 PORTER'S 5 FORCES 71
  • 4.3 EPIDEMIOLOGY 72

5 GLOBAL UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK 73

  • 5.1 OVERVIEW 73
  • 5.2 REGULATION IN THE U.S. 74
  • 5.3 REGULATION IN CANADA 74
  • 5.4 REGULATION IN EUROPE 74
  • 5.5 REGULATION IN CHINA 74
  • 5.6 REGULATION IN JAPAN 74
  • 5.7 REGULATION IN AUSTRALIA 75
  • 5.8 REGULATION IN INDIA 75
  • 5.9 REGULATION IN BRAZIL 75
  • 5.10 REGULATION IN SOUTH AFRICA 75

6 MARKET OVERVIEW 76

  • 6.1 DRIVERS 78
    • 6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE 78
    • 6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER 79
    • 6.1.3 RISING AWARENESS OF UTERINE CANCER 80
    • 6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS 81
  • 6.2 RESTRAINTS 82
    • 6.2.1 HIGH COST OF UTERINE CANCER TREATMENT 82
    • 6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS 83
  • 6.3 OPPORTUNITIES 84
    • 6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY 84
    • 6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT 85
  • 6.4 CHALLENGES 86
    • 6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET 86
    • 6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER 87

7 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE 89

  • 7.1 OVERVIEW 90
  • 7.2 ENDOMETRIAL CANCER 93
    • 7.2.1 UTERINE CARCINOSARCOMA 94
    • 7.2.2 SEROUS ADENOSARCOMA 94
    • 7.2.3 ADENOSQUAMOUS CARCINOMA 94
    • 7.2.4 OTHER 94
  • 7.3 UTERINE SARCOMA 95
    • 7.3.1 UTERINE LEIOMYOSARCOMA 95
    • 7.3.2 ENDOMETRIAL STROMAL SARCOMAS 95
    • 7.3.3 UNDIFFERENTIATED SARCOMA 96

8 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE 97

  • 8.1 OVERVIEW 98
  • 8.2 CHEMOTHERAPY 101
    • 8.2.1 PACLITAXEL 102
    • 8.2.2 CARBOPLATIN 102
    • 8.2.3 CISPLATIN 102
    • 8.2.4 DOXORUBICIN 102
    • 8.2.5 DOCETAXEL 102
    • 8.2.6 OTHERS 102
  • 8.3 IMMUNOTHERAPY 103

 

  • 8.4 HORMONE THERAPY 103
    • 8.4.1 PROGESTINS 104
      • 8.4.1.1 MEDROXYPROGESTERONE ACETATE 104
      • 8.4.1.2 OTHERS 104
    • 8.4.2 AROMATASE INHIBITORS 105
      • 8.4.2.1 LETRAZOLE 105
      • 8.4.2.2 ANASTRAZOLE 105
      • 8.4.2.3 EXEMESTANE 105
    • 8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS 106
      • 8.4.3.1 GOSERELIN 106
      • 8.4.3.2 LEUPROLIDE 106
    • 8.4.4 OTHERS 106
  • 8.5 TARGETED THERAPY 107
    • 8.5.1 LENVATINAB 107
    • 8.5.2 BEVACIZUMAB 107
    • 8.5.3 MTOR INHIBITORS 107
      • 8.5.3.1 EVEROLIMUS 108
      • 8.5.3.2 TEMSIROLIMUS 108
  • 8.6 OTHERS 108

9 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE 109

  • 9.1 OVERVIEW 110
  • 9.2 GENERICS 113
  • 9.3 BRANDED 113
    • 9.3.1 KEYTRUDA 114
    • 9.3.2 LENVIMA 114
    • 9.3.3 PROVERA 115
    • 9.3.4 TEMODAR 115
    • 9.3.5 JEMPERLI 115
    • 9.3.6 OTHERS 115

10 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP 116

  • 10.1 OVERVIEW 117
  • 10.2 GERIATRIC 120
  • 10.3 ADULTS 120

11 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 121

  • 11.1 OVERVIEW 122
  • 11.2 PARENTERAL 125
  • 11.3 ORAL 125

 

12 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER 126

  • 12.1 OVERVIEW 127
  • 12.2 HOSPITALS 130
    • 12.2.1 PRIVATE 130
    • 12.2.2 PUBLIC 130
  • 12.3 CANCER CENTERS 131
  • 12.4 SPECIALTY CLINICS 131
  • 12.5 OTHERS 132

13 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 133

  • 13.1 OVERVIEW 134
  • 13.2 DIRECT TENDER 137
  • 13.3 RETAIL SALES 137
    • 13.3.1 HOSPITAL PHARMACY 138
    • 13.3.2 RETAIL PHARMACY 138
    • 13.3.3 ONLINE PHARMACY 138
  • 13.4 OTHERS 139

14 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION 140

  • 14.1 OVERVIEW 141
  • 14.2 NORTH AMERICA 145
    • 14.2.1 U.S. 151
    • 14.2.2 CANADA 156
    • 14.2.3 MEXICO 161
  • 14.3 EUROPE 166
    • 14.3.1 GERMANY 172
    • 14.3.2 U.K. 177
    • 14.3.3 FRANCE 182
    • 14.3.4 RUSSIA 187
    • 14.3.5 ITALY 192
    • 14.3.6 SPAIN 197
    • 14.3.7 TURKEY 202
    • 14.3.8 BELGIUM 207
    • 14.3.9 NETHERLANDS 212
    • 14.3.10 SWITZERLAND 217
    • 14.3.11 REST OF EUROPE 222

 

  • 14.4 ASIA-PACIFIC 223
    • 14.4.1 CHINA 229
    • 14.4.2 JAPAN 234
    • 14.4.3 INDIA 239
    • 14.4.4 AUSTRALIA 244
    • 14.4.5 SOUTH KOREA 249
    • 14.4.6 NEW ZEALAND 254
    • 14.4.7 SINGAPORE 259
    • 14.4.8 THAILAND 264
    • 14.4.9 MALAYSIA 269
    • 14.4.10 INDONESIA 274
    • 14.4.11 PHILIPPINES 279
    • 14.4.12 REST OF ASIA-PACIFIC 284
  • 14.5 SOUTH AMERICA 285
    • 14.5.1 BRAZIL 291
    • 14.5.2 ARGENTINA 296
    • 14.5.3 REST OF SOUTH AMERICA 301
  • 14.6 MIDDLE EAST AND AFRICA 302
    • 14.6.1 SAUDI ARABIA 308
    • 14.6.2 U.A.E. 313
    • 14.6.3 SOUTH AFRICA 318
    • 14.6.4 EGYPT 323
    • 14.6.5 KUWAIT 328
    • 14.6.6 REST OF MIDDLE EAST AFRICA 333

15 GLOBAL UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE 334

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 334
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 335
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 336
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 337

16 SWOT ANALYSIS 338

17 COMPANY PROFILES 339

  • 17.1 MERCK & CO., INC. 339
    • 17.1.1 COMPANY SNAPSHOT 339
    • 17.1.2 REVENUE ANALYSIS 339
    • 17.1.3 COMPANY SHARE ANALYSIS 340
    • 17.1.4 PRODUCT PORTFOLIO 340
    • 17.1.5 RECENT DEVELOPMENT 341

 

  • 17.2 EISAI CO., LTD. 342
    • 17.2.1 COMPANY SNAPSHOT 342
    • 17.2.2 REVENUE ANALYSIS 342
    • 17.2.3 COMPANY SHARE ANALYSIS 343
    • 17.2.4 PRODUCT PORTFOLIO 343
    • 17.2.5 RECENT DEVELOPMENT 343
    • 17.2.6 RECENT DEVELOPMENT 344
  • 17.3 SANOFI 345
    • 17.3.1 COMPANY SNAPSHOT 345
    • 17.3.2 REVENUE ANALYSIS 345
    • 17.3.3 COMPANY SHARE ANALYSIS 346
    • 17.3.4 PRODUCT PORTFOLIO 346
    • 17.3.5 RECENT DEVELOPMENT 347
  • 17.4 PFIZER INC. 348
    • 17.4.1 COMPANY SNAPSHOT 348
    • 17.4.2 REVENUE ANALYSIS 348
    • 17.4.3 COMPANY SHARE ANALYSIS 349
    • 17.4.4 PRODUCT PORTFOLIO 349
    • 17.4.5 RECENT DEVELOPMENT 351
  • 17.5 TEVA PHARMACEUTICALS USA, INC. 352
    • 17.5.1 COMPANY SNAPSHOT 352
    • 17.5.2 REVENUE ANALYSIS 352
    • 17.5.3 PRODUCT PORTFOLIO 353
    • 17.5.4 RECENT DEVELOPMENT 353
  • 17.6 ACCORD HEALTHCARE US. 354
    • 17.6.1 COMPANY SNAPSHOT 354
    • 17.6.2 PRODUCT PORTFOLIO 354
    • 17.6.3 RECENT DEVELOPMENT 354
  • 17.7 AMNEAL PHARMACEUTICALS LLC 355
    • 17.7.1 COMPANY SNAPSHOT 355
    • 17.7.2 REVENUE ANALYSIS 355
    • 17.7.3 PRODUCT PORTFOLIO 356
    • 17.7.4 RECENT DEVELOPMENT 356
  • 17.8 BAXTER 357
    • 17.8.1 COMPANY SNAPSHOT 357
    • 17.8.2 REVENUE ANALYSIS 357
    • 17.8.3 COMPANY SHARE ANALYSIS 358
    • 17.8.4 PRODUCT PORTFOLIO 358
    • 17.8.5 RECENT DEVELOPMENT 358

 

  • 17.9 ELI LILLY AND COMPANY 359
    • 17.9.1 COMPANY SNAPSHOT 359
    • 17.9.2 REVENUE ANALYSIS 360
    • 17.9.3 PRODUCT PORTFOLIO 360
    • 17.9.4 RECENT DEVELOPMENT 361
  • 17.10 GETWELL ONCOLOGY 362
    • 17.10.1 COMPANY SNAPSHOT 362
    • 17.10.2 PRODUCT PORTFOLIO 362
    • 17.10.3 RECENT DEVELOPMENT 365
  • 17.11 GSK PLC. 366
    • 17.11.1 COMPANY SNAPSHOT 366
    • 17.11.2 REVENUE ANALYSIS 366
    • 17.11.3 PRODUCT PORTFOLIO 367
    • 17.11.4 RECENT DEVELOPMENT 367
  • 17.12 HIKMA PHARMACEUTICALS PLC 368
    • 17.12.1 COMPANY SNAPSHOT 368
    • 17.12.2 REVENUE ANALYSIS 368
    • 17.12.3 PRODUCT PORTFOLIO 369
    • 17.12.4 RECENT DEVELOPMENT 369
  • 17.13 SUN PHARMACEUTICAL INDUSTRIES LTD. 370
    • 17.13.1 COMPANY SNAPSHOT 370
    • 17.13.2 REVENUE ANALYSIS 370
    • 17.13.3 PRODUCT PORTFOLIO 371
    • 17.13.4 RECENT DEVELOPMENT 371
  • 17.14 VIATRIS INC. 372
    • 17.14.1 COMPANY SNAPSHOT 372
    • 17.14.2 REVENUE ANALYSIS 372
    • 17.14.3 PRODUCT PORTFOLIO 373
    • 17.14.4 RECENT DEVELOPMENT 373
  • 17.15 VIRTUS 374
    • 17.15.1 COMPANY SNAPSHOT 374
    • 17.15.2 PRODUCT PORTFOLIO 374
    • 17.15.3 RECENT DEVELOPMENT 374

18 QUESTIONNAIRE 375

19 RELATED REPORTS 379

  • 17.15 VIRTUS 374
    • 17.15.1 COMPANY SNAPSHOT 374
    • 17.15.2 PRODUCT PORTFOLIO 374
    • 17.15.3 RECENT DEVELOPMENT 374

18 QUESTIONNAIRE 375

19 RELATED REPORTS 379

LIST OF FIGURES

  • FIGURE 1 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION 52
  • FIGURE 2 GLOBAL UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION 55
  • FIGURE 3 GLOBAL UTERINE CANCER DRUGS MARKET: DROC ANALYSIS 56
  • FIGURE 4 GLOBAL UTERINE CANCER DRUGS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 57
  • FIGURE 5 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS 57
  • FIGURE 6 GLOBAL UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS 59
  • FIGURE 7 GLOBAL UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID 60
  • FIGURE 8 GLOBAL UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID 61
  • FIGURE 9 GLOBAL UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS 62
  • FIGURE 10 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION 66
  • FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 67
  • FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030 67
  • FIGURE 13 NORTH AMEIRCA IS EXPECTED TO DOMINATE THE GLOBAL UTERINE CANCER DRUGS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 68
  • FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR UTERINE CANCER DRUG MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 69
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL UTERINE CANCER DRUGS MARKET 77
  • FIGURE 16 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022 90
  • FIGURE 17 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND) 91
  • FIGURE 18 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030) 91
  • FIGURE 19 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE 92
  • FIGURE 20 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022 98
  • FIGURE 21 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 99
  • FIGURE 22 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 99
  • FIGURE 23 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 100
  • FIGURE 24 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022 110
  • FIGURE 25 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND) 111
  • FIGURE 26 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030) 111
  • FIGURE 27 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE 112
  • FIGURE 28 GLOBAL UTERINE CANCER DRUGS MARKET: BY TYPE, 2022 117
  • FIGURE 29 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND) 118
  • FIGURE 30 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030) 118
  • FIGURE 31 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE 119
  • FIGURE 32 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022 122
  • FIGURE 33 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 123
  • FIGURE 34 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 123
  • FIGURE 35 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 124
  • FIGURE 36 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2022 127
  • FIGURE 37 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND) 128
  • FIGURE 38 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030) 128
  • FIGURE 39 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE 129
  • FIGURE 40 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022 134
  • FIGURE 41 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 135
  • FIGURE 42 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 135
  • FIGURE 43 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 136
  • FIGURE 44 GLOBAL UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022) 142
  • FIGURE 45 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 334
  • FIGURE 46 NORTH AMERICA UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 335
  • FIGURE 47 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 336
  • FIGURE 48 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 337